$CELG Recent News The market puts a few feathers in its

New Post Public Reply Private Reply Replies (0) Message Board

Feb 25, 2014 at 12:47 PM

$CELG Recent News

The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Celgene's 2014 guidance falls below analyst views 12:19 p.m. Jan. 13, 2014 - MarketWatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck

Putting the biotech boom in perspective 12:54 p.m. Feb. 24, 2014 - Seeking Alpha
What To Buy: Celgene Corporation's Buy Recommendation Reiterated 9:00 a.m. Feb. 24, 2014 - TheStreet.com
Catalysts Drive These Stocks: Mara Goldstein 9:20 a.m. Feb. 21, 2014 - Seeking Alpha
Can CELG Clear Key Resistance? 9:00 a.m. Feb. 21, 2014 - RealMoney.com
Placenta Based Treatments Crowding Out Legacy Products In Wound Care 8:34 a.m. Feb. 21, 2014 - Seeking Alpha
Who Is Responsible For Biotech's Torrid Start to 2014? 4:03 p.m. Feb. 20, 2014 - TheStreet.com
REGN, BIIB And CELG, Pushing Drugs Industry Downward 12:04 p.m. Feb. 19, 2014 - TheStreet.com
Celgene Corporation (CELG): Today's Featured Health Care Winner 5:00 p.m. Feb. 18, 2014 - TheStreet.com
Celgene Plans Stock Split - Analyst Blog 5:34 p.m. Feb. 14, 2014 - Zacks.com
Big Pharma Will Find Good Hunting Among Early-Stage Biotechs: Dhesh Govender 11:56 a.m. Feb. 14, 2014 - Seeking Alpha
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
10-K: CELGENE CORP /DE/ 4:04 p.m. Feb. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
Market Wrap For February 13: Markets Close Higher; Nasdaq on a Six Day Winning Streak 3:50 p.m. Feb. 13, 2014 - benzinga.com
Regenerative Medicine Finally Gets Some Respect: Reni Benjamin 9:23 a.m. Feb. 13, 2014 - Seeking Alpha
IPO Preview: Concert Pharmaceuticals 1:00 a.m. Feb. 13, 2014 - Seeking Alpha
Jim Cramer's 6 Stocks in 60 Seconds: BUD S LNG VJET SGEN CROX 5:08 p.m. Feb. 12, 2014 - TheStreet.com
Short Sellers Shy Away From Biotechs 6:04 a.m. Feb. 12, 2014 - 247WallSt.com
Celgene Corporation Continues With Buy Recommendation 9:00 a.m. Feb. 11, 2014 - TheStreet.com
Health Canada Approves (Pr)POMALYST(TM) (Pomalidomide Capsules) Providing New Hope For Patients With Progressive Multiple Myeloma 6:30 a.m. Feb. 11, 2014 - CNW Group
You Can No Longer Ignore Biotech 4:32 p.m. Feb. 7, 2014 - GuruFocus.com

Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split 7:30 a.m. Feb. 13, 2014 - BusinessWire - BZX
Celgene Corporation to Present at Investor Conferences in February and March 8:30 a.m. Feb. 11, 2014 - BusinessWire - BZX
Grant & Eisenhofer Represents Whistleblower Accusing Celgene Corp. of Off-Label Marketing of High-Risk Cancer Drugs Derived from Thalidomide 2:11 p.m. Feb. 6, 2014 - PR Newswire - PRF
Critical Alerts For Baidu.com, Endo Pharmaceuticals, Mattel, Celgene, and Tyson Foods Released By InvestorsObserver 9:31 a.m. Feb. 4, 2014 - PR Newswire - PRF
Celgene Reports Fourth Quarter and Full Year 2013 Operating and Financial Results 7:32 a.m. Jan. 30, 2014 - BusinessWire - BZX
Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014 8:30 a.m. Jan. 22, 2014 - BusinessWire - BZX
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results 11:29 a.m. Jan. 13, 2014 - BusinessWire - BZX
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Summit Midstream Prepares for Q3 2026 Earnings Report

Quarterly financials are the canary in the coal mine for any energy firm. Scrutinizing those numbers can be the difference between riding a bull market or nursing your wounds in a ditch. So, what's on tap for Summit Midstream Corporation (NYSE: SMC)? They've circled November 9, 2026, on the calendar for releasing their third quarter figures, just after the NYSE bell...

TETRA Hits High Mark with Robust Q3 Earnings Surge

Financial Milestones and Market Insights Boy, if you're not watching TETRA Technologies (NYSE:TTI) right now, you're probably missing out on a real barnstormer of a financial report. The numbers are looking chalkboards-be-damned stellar! They’ve just notched their finest third quarter in a decade, bringing in revenues through the roof at $168 million—an impressive 10%...

Cboe Fights CFTC Over Single-Stock Derivative Approval

The Battle Begins: Cboe's Legal Action Cboe Global Markets, the big kahuna in the equities and index derivatives scene, ain't just rolling over quietly. They've hopped on board with the Capital Markets Alliance in a legal dust-up against the Commodity Futures Trading Commission's (CFTC) decision to allow perpetual derivatives on U.S. stocks and ETFs. We're talking major...

Katie Lee: Embracing Losses for Business Success

Redefining Adversity Through Business Acumen You'd think building a business empire requires nothing short of pure triumph, yet Katie Lee sings a different tune altogether. Lee's path from high school dropout to a prominent figure in the culinary world is paved with setbacks—albeit ones she wears like badges of honor. This November 18th, catch her at the New York Public...

China-CEEC Forum Sparks Robust SME Partnerships

There’s a fresh buzz around Cangzhou's efforts to galvanize business opportunities between China and Central and Eastern Europe. The 7th China-CEEC SME Forum, kicking off in this city of Hebei Province, isn’t just another meeting of the minds. Nope, it’s like a marketplace thrown into overdrive—where AI strategies and logistics are shaping up to be the star...

Swif.ai Paves Linux Path for Enterprise Developers

The Quiet Revolution: Linux Takes Center Stage Linux, once the underdog of operating systems, is gaining significant traction in the world of AI development. It's not just a nerd's sandbox anymore; it's rapidly becoming the go-to platform for cutting-edge AI innovation. Now, more enterprise IT departments are facing the choice of keeping up with Linux's popularity—or...

ACLM and eClinicalWorks Expand Lifestyle Medicine Reach

Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...

Goodal Skincare Capitalizes on K-Beauty Craze at Costco

A Venture into American Retail Goodal, the darling of Korea's skincare scene, is staking its claim at Costco. This is no small feat, my friends. We're talkin' about a brand that's carved out a sweet niche with its Green Tangerine line. Now it's hitching its wagon to one of America's retail behemoths, known for its unique knack in beauty products. From Olive Young to...

Geopolitical Talks Shake Oil Market, Refine Stocks' Path

Diplomacy Takes Center Stage So here we are again, riding the rollercoaster of geopolitics that's jerking the oil market around like a marionette. With the U.S. and Iran allegedly chatting—mind you, with a ton of smoke and mirrors through Qatar and Islamabad—every trader's watching, hoping for a ceasefire that might either stabilize or further jolt energy prices. Oil...

AEYE Health's AI Triumph: Preventing Blindness on the Move

Making Diabetic Eye Exams Effortless Folks, the healthcare landscape just got a jolt from an unexpected corner. AEYE Health, with its AI wizardry, snagged the 2026 Prix Galien USA Award. This ain't your run-of-the-mill blue ribbon from a county fair; it's a heavyweight title in the world of medical innovation. The harbinger of this change? AEYE-DS, an AI-packed gadget...